<div><p><strong><b>Background:</strong> </b>Alcohol-associated liver disease (ALD) is a major public health problem worldwide, and gut microbial dysbiosis is an important contributor to ALD pathogenesis. Our previous study showed that patients with alcohol-associated hepatitis (AH) have increased proportions of mammalian viruses including retroviruses in the fecal virome. However, the role of the gut virome and in particular of endogenous retroviruses (ERVs) for ALD development is unknown.

<div><p><b>Background: </b>Bulevirtide (BLV), a novel hepatitis delta virus (HDV) entry inhibitor, is approved in Europe for treatment of chronic hepatitis D (CHD). In clinical studies, virologic response (VR) was defined as undetectable HDV RNA or ≥2-log₁₀IU/mL decline from baseline (BL). Optimal BLV monotherapy duration for CHD is unknown; it is also unclear whether continued therapy will benefit patients (pts) with early virologic nonresponse (NR) or partial response (PR).

<div><p><b>Background: </b>Contrast-enhanced ultrasound (CEUS) is a promising diagnostic technique for hepatocellular carcinoma (HCC) diagnosis. While EASL HCC guidelines endorse its use in cases of inconclusive CT or MRI based on non-focused studies, the diagnostic potential of CEUS for HCC is not currently recognized by AASLD guidelines. This study aimed to assess the clinical impact of CEUS specifically in cases where liver lesions were indeterminate on MRI.</p>

<div><p><b>Background: </b>Acute kidney injury (AKI) frequently complicates the course of hospitalized patients with cirrhosis and negatively impacts prognosis. Response to medical management in AKI is variable, depending on the etiology and severity of the injury. How AKI improvement or response affects liver transplant timing is less clear. We sought to assess the impact of AKI response to treatment on survival and liver transplantation (LT) for patients with cirrhosis waitlisted for LT.</p>

<div><p><b>Background:<strong> </b><span> </span></strong>Hepatic steatosis (HS) and a 10-year atherosclerotic cardiovascular disease (ASCVD) risk of ≥7.5% are associated with increased risk for future cardiovascular events. However, cardiovascular risk of patients with HS at ASCVD&lt;7.5% is not clearly understood.</p>

<div><p><b>Background:</p> </b><p>We previously showed that loss of Yes-associated protein 1 (YAP) in early liver development (YAP^KO) leads to an Alagille syndrome-like phenotype, with failure of intrahepatic bile duct development, severe cholestasis, and chronic hepatocyte adaptations to reduce liver injury. TAZ, a paralog of YAP, was significantly upregulated in YAP^KO hepatocytes and interacted with TEAD transcription factors, suggesting possible compensatory activity.</p>

<div><p><b>Background:<span> </b>Progressive familial intrahepatic cholestasis (PFIC) are a group of recessive disorders linked by the inability to appropriately excrete bile salts (BS) from hepatocytes. PFIC1 results from mutations in <em>ATP8B1 </em>encoding FIC1, an apical membrane aminophospholipid translocase.

<div><p><b>Background:</p> </b><div><p><span lang="EN-US">In the context of alcohol-related liver disease (ArLD), changes in the homeostasis of the gut-liver axis have become a focus of major </span></p></div>

<div><p><b>Background:</p> </b><p>Acute variceal bleeding (AVB) is a cause of serious morbidity and mortality in cirrhosis. While more severe disease (e.g. higher Child-Turcotte-Pugh [CTP] score) has been shown to correlate with worse outcomes after AVB, it is unclear if this correlation remains universal across all cirrhosis etiologies.

<div><p><strong>Background</strong>: Minimal hepatic encephalopathy (MHE) is associated with poor outcomes but treatment strategies are limited. Rifamycin SV MMX (RiVM) is a novel rifampin derivative which a non-absorbable antibiotic with maximal impact in the colon. <u>Aim</u>: Evaluate impact of RiVM on microbiome, safety &amp; gut-brain axis in an RCT.</p>